Figure 4.

Permeability measured using Bodipy Ouabain in unstretched type I–like RAECs. The cells were treated with VC or with the nitric oxide donor SNAP or with the superoxide donor paraquat. Simultaneously with each donor, we treated the cells with the NF-κB activation inhibitor MG132, extracellular signal–regulated kinase pathway blocker U0126, or a combination of both. Data are expressed as mean ± SEM of fold change above unstretched cells treated with VC. *P < 0.05 versus unstretched VC. ^†P < 0.05 versus unstretched SNAP. ^††P < 0.05 versus unstretched paraquat.